Sotera Health Reports 2024 Earnings and 2025 Outlook

Sotera Health Company ( (SHC) ) has released its Q4 earnings. Here is a breakdown of the information Sotera Health Company presented to its investors.

Sotera Health Company is a global leader in providing essential sterilization solutions, lab testing, and advisory services for the healthcare industry. The company operates through its three main businesses: Sterigenics, Nordion, and Nelson Labs, and is dedicated to its mission of safeguarding global health.

In its latest earnings report, Sotera Health announced a 4.9% increase in net revenues for the full year 2024, reaching $1.10 billion. The company also reported a net income of $44 million, or $0.16 per diluted share. Despite a decrease in fourth-quarter revenues, the company achieved several milestones, including strong customer satisfaction scores and expansion of its Sterigenics facility.

Key financial highlights for 2024 include a 3.9% increase in adjusted EBITDA to $549 million and a slight decrease in adjusted EPS to $0.70. The Sterigenics segment showed revenue growth, while Nordion experienced a decline in fourth-quarter revenues due to cobalt harvest schedules. Nelson Labs also saw a decrease in fourth-quarter revenues but maintained growth for the full year.

Looking ahead to 2025, Sotera Health anticipates net revenue growth between 4.0% and 6.0% and adjusted EBITDA growth between 4.5% and 6.5%, despite expected foreign currency headwinds. The company remains focused on serving its customers and maintaining its commitment to global health.